Welcome to our dedicated page for New Jersey Res SEC filings (Ticker: NJR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking utility margins, solar tax credits, and midstream pipeline rulings across hundreds of pages can be daunting. New Jersey Resources鈥� filings blend regulated utility math with commodity hedging tables and renewable project accounting鈥攄etails many investors struggle to locate quickly.
Our platform solves this. Stock Titan鈥檚 AI reads every New Jersey Resources annual report 10-K simplified, each New Jersey Resources quarterly earnings report 10-Q filing, and all New Jersey Resources 8-K material events explained, then distills the essentials: rate-base growth, Clean Energy Ventures returns, and pipeline milestone updates. Need to follow New Jersey Resources insider trading Form 4 transactions? Receive New Jersey Resources Form 4 insider transactions real-time alerts, complete with plain-English summaries of executive buys and sells.
Inside the Filings tab you鈥檒l find:
- AI-powered summaries that make understanding New Jersey Resources SEC documents with AI straightforward.
- Side-by-side metrics that power New Jersey Resources earnings report filing analysis, including seasonal volume swings.
- Direct links to the definitive New Jersey Resources proxy statement executive compensation sections鈥攗seful when benchmarking pay against peers.
Whether you鈥檙e scanning a footnote on deferred solar ITCs or verifying New Jersey Resources executive stock transactions Form 4, every filing arrives from EDGAR in real time and is instantly parsed. Skip the page-count fatigue and focus on decisions鈥攐ur expert analysis surfaces the datapoints that move valuations.
Windtree Therapeutics (WINT) 8-K: On 29-Jul-2025 director Leanne Kelly resigned from the Board and as Audit Committee chair, effective immediately. The filing gives no reason for her departure.
On 3-Aug-2025 the Board appointed Andrew Kucharchuk鈥攃urrently CFO of Cero Therapeutics Holdings and an experienced biotech financial executive鈥攖o fill the vacant seat and assume the Audit Committee chairmanship. The Board confirmed his independence under Nasdaq and SEC rules.
No related-party dealings, inducement equity grants, or special compensation were disclosed; he will receive only standard Board cash fees. His term runs until a successor is elected or otherwise removed.
- Governance continuity re-established within five days of resignation.
- Audit Committee independence preserved, mitigating internal-control risk.
Form 4 filing overview: On 2 July 2025, New Jersey Resources Corp. (NJR) reported that non-employee director William T. Yardley received 1,504.306 Restricted Stock Units (RSUs) on 1 July 2025 under the company鈥檚 Non-Employee Director Compensation Plan. Each RSU represents one share of NJR common stock plus accrued dividend equivalents.
Key details
- Type of security: Derivative 鈥� RSUs
- Transaction code: 鈥淎鈥� (grant/award)
- Price paid: $0 (equity compensation)
- Vesting: Earliest of (i) 1-year anniversary of grant or (ii) the next NJR annual meeting of shareowners.
- Post-transaction holding: 1,504.306 RSUs held directly by the director.
No open-market purchase or sale of common shares occurred; the filing simply reflects routine annual equity compensation. The award is immaterial to NJR鈥檚 share count and has negligible dilution impact, but slightly increases director ownership, marginally aligning board and shareholder interests.
The filing is a Form 144 notice, indicating that a holder intends to sell American Depositary Shares (ADS) of the issuer identified in the header as 鈥淏eOne Medicines Ltd.鈥�.
- Securities to be sold: 3,174 ADS
- Estimated market value: $830,359.98
- Planned sale date: 06/23/2025 on the NASDAQ
- Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York
The seller, John Oyler, has also disposed of 10,267 ADS during the past three months in three separate transactions, generating aggregate gross proceeds of approximately $2.65 million.
The new sale, together with recent transactions, suggests continued insider liquidation. Relationship to the issuer is not disclosed in the form, and the filer affirms no undisclosed adverse information. No additional financial statements or operational details are provided in this notice.
FAQ
What is the current stock price of New Jersey Res (NJR)?
What is the market cap of New Jersey Res (NJR)?
What are the main business segments of New Jersey Resources?
How does NJR ensure reliable service in its regulated utility segment?
What role does infrastructure play in NJR's operations?
How does New Jersey Resources diversify its portfolio?
What competitive advantages does NJR have in the energy industry?
How are safety and operational excellence maintained at NJR?
What geographic areas are served by NJR's regulated utility services?
How does NJR's investment in solar energy fit into its overall business model?
